Improving AAV gene therapy for muscle diseases
Overcoming limitations for AAV gene therapy
This project develops better AAV gene therapy tools to help people with muscular dystrophies like Duchenne and FSHD.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11190909 on NIH RePORTER |
What this research studies
The team is designing and testing new AAV capsids and gene expression cassettes to deliver stronger, less immunogenic dystrophin constructs to skeletal and heart muscle. They are iteratively testing different micro-dystrophins, split-intein larger dystrophins, and muscle-specific cassette designs to boost potency and reduce immune reactions. For FSHD, they are developing enhanced AAV-RNAi cassettes to knock down the harmful DUX4 transcript. Tests use human iPSC-derived 3D muscle tissues and animal models to measure safety and function before moving toward clinical use.
Who could benefit from this research
Good fit: People with Duchenne muscular dystrophy, certain limb-girdle dystrophies, X-linked myotubular myopathy, or FSHD who are interested in future gene therapy approaches would be the most relevant candidates.
Not a fit: Patients with muscle problems not caused by the targeted genes, those with very advanced irreversible muscle damage, or those with immune conditions that prevent AAV use may not benefit.
Why it matters
Potential benefit: If successful, this work could produce safer, longer-lasting AAV gene therapies that improve muscle strength and heart function for people with muscular dystrophy.
How similar studies have performed: Early AAV micro-dystrophin clinical efforts have shown promising results but have not fully restored function, while DUX4-targeting approaches are still more experimental.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Chamberlain, Jeffrey S — University of Washington
- Study coordinator: Chamberlain, Jeffrey S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.